Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viking Systems: Implementing a Public Start-Up Model

This article was originally published in Start Up

Executive Summary

A year ago, Viking Systems Inc. reinvented itself based on the belief that it has found a way to take advantage of the public model to acquire small medical device companies and provide incentives to their entrepreneurial founders to work towards the greater good of an integrated company. Viking will use combinations of stock, cash, and royalties tied to the future performance of products to acquire companies, products or services for the surgical suite that have strong intellectual property and revenues in the $500,000 to $10 million range. The idea is to take advantage of the medical device industry's fragmentation, both in terms of the large number of one-product companies that exist, and the requirement, in Viking's new target market-minimally invasive surgery--for numerous parts and pieces found within different types of companies. Its first acquisition was the visualization business of Vista Medical Technologies.

You may also be interested in...



Teleflex: Hospital Supply's Best Kept Secret

The name Teleflex barely registers among most device executives and hospital customers, but the company's individual brands, Weck, Pilling, and Rusch, are well-known. Teleflex's greatest challenge lies in finding a middle ground between its niche approach, built on the strong brands of its individual businesses, and the resources available from a larger, coordinated corporate effort. It's an issue of identity: can Teleflex ever be anything other than a collection of strong brands?

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel